Comparative Pharmacology
Head-to-head clinical analysis: FLAREX versus PREDNISOLONE EYE DROPS.
Peer-Reviewed Evidence
Head-to-head clinical analysis: FLAREX versus PREDNISOLONE EYE DROPS.
FLAREX vs Prednisolone Eye Drops
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Corticosteroid that inhibits phospholipase A2 activity, reducing arachidonic acid release and subsequent production of prostaglandins and leukotrienes, thereby suppressing ocular inflammation.
Corticosteroid that binds to glucocorticoid receptors, modulating gene expression and suppressing inflammatory mediators such as prostaglandins and leukotrienes.
1-2 drops in the conjunctival sac every hour during the day and every 2 hours at night initially; after response, reduce to 1 drop every 4 hours, then 1 drop 3-4 times daily. Ophthalmic suspension.
Instill 1-2 drops into the conjunctival sac of the affected eye(s) four times daily. In severe cases, dosing may be initiated with 1-2 drops every 1-2 hours and tapered upon improvement.
None Documented
None Documented
Terminal elimination half-life is approximately 1-2 hours (mean 1.3 hours) in adults. Due to rapid clearance, accumulation is minimal with topical ophthalmic dosing, but prolonged use may lead to systemic absorption and slightly extended half-life.
Plasma: 2-4 hours; tissue effects persist 18-36 hours. Clinically, duration of adrenal suppression may exceed plasma half-life.
Primarily hepatic metabolism, with inactive metabolites excreted renally (approximately 60-80%) and fecally (20-40%). Less than 5% of unchanged drug appears in urine.
Renal (primarily as metabolites): ~70% after oral dose; unchanged drug: <20%. Biliary/fecal: minor.
Category C
Category A/B
Ophthalmic Corticosteroid
Ophthalmic Corticosteroid